Location History:
- Bethesda, MD (US) (2008 - 2015)
- Rockville, MD (US) (2014 - 2024)
Company Filing History:
Years Active: 2008-2025
Title: The Innovative Mind of J Andrew Bristol: Pioneering Cancer Research through Patents
Introduction: J Andrew Bristol, based in Rockville, MD, has made significant contributions to the field of cancer research, particularly through his innovative work in the development of recombinant monoclonal antibodies. With a total of 14 patents to his name, Bristol has established himself as a prominent figure among inventors in the biotech industry.
Latest Patents: Among his most recent inventions are patent filings that focus on recombinant monoclonal antibodies and corresponding antigens specifically targeting colon and pancreatic cancers. His work includes providing highly pure recombinant monoclonal antibodies that bind to colorectal and pancreatic carcinoma-associated antigens, alongside nucleic acid sequences that encode the antibody chains. These patents not only represent a significant advancement in cancer treatment methodologies but also hold potential for future therapeutic applications aimed at improving patient outcomes.
Career Highlights: Throughout his career, J Andrew Bristol has collaborated with notable companies such as Precision Biologics, Inc. and Neogenix Oncology, Inc. His efforts in these organizations highlight his dedication to advancing cancer research and finding innovative solutions through technology and biology. Bristol’s numerous patents are a testament to his commitment to pushing the boundaries of current medical science.
Collaborations: In his journey, he has worked alongside esteemed colleagues like Myron Arlen and Kwong Y Tsang. These collaborations have not only enriched his work but have also opened doors for further innovations in the realm of immunotherapy and cancer treatment strategies.
Conclusion: J Andrew Bristol's continued dedication and creativity in developing groundbreaking solutions to complex cancer challenges exemplify the essence of innovation in the medical field. With a robust portfolio of patents and a history of impactful collaboration, Bristol stands as a key inventor whose work promises to enhance therapeutic outcomes for cancer patients globally.